-
Nexus surges as pharma’s fastest-growing lobbyist
When it comes to the lobbying firm pharma companies are turning to in Canberra, Nexus APAC is now the clear frontrunner.
1 day ago | In Companies, Politics -
Health tries to justify failed PBAC recommendations
The Department of Health tries to justify why more than 50 older PBAC recommendations failed to secure PBS listing, mostly by pinning the blame on sponsors.
1 day ago | In Patients, Politics, Reimbursement -
Corporate manoeuvres a bigger threat than MFN
Manufacturers’ global pricing tactics may undermine MFN‑linked GLOBE and GUARD savings and push international drug prices even higher.
1 day ago | In Companies, Industry, Politics -
Will LillyDirect deliver more than medicines?
The Pharmacy Guild has won support from unlikely quarters in its attack on LillyDirect, leaving the pharma company at risk of serious reputational damage.
3 days ago | In Comment, Patients, Reputation -
GSK attracts BMS leader as Lilly ‘restructures’
GSK secures a BMS senior executive to lead its oncology portfolio as a restructure at Lilly sees at least one leader looking for a new role.
3 days ago | In Companies, People -
Government says newborn screening goal met
Despite 34 of 42 identified conditions not progressing, Labor says it has fulfilled its commitment to increase the number of conditions screened to world’s best.
3 days ago | In Politics -
AZ Code breach has wider ramifications
Promoting a PBS listing that was broader than the TGA indication earned AZ a $120,000 fine and will likely see other companies revisit their HCP messaging.
1 week ago | In Companies, Products, Reputation
Comment
Lilly set to disrupt medicines supply chain
LillyDirect may well be to community pharmacy what Uber was to taxis; taxis are still there, but if given a choice, most people choose Uber.
News In Brief
US Administration releases GLOBE framework
The Final Rule positions GLOBE as a narrower, more targeted mechanism than originally proposed but still embeds international reference pricing into US federal regulation.
Top Reads
-
-
Fri Oct 2
AZ Code breach has wider ramifications
-
-
Fri Oct 2
Novartis bids farewell to popular leader
-